These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 18558304)

  • 121. Management of metabolic bone disease in kidney transplant recipients.
    Zhang R; Alper B; Simon E; Florman S; Slakey D
    Am J Med Sci; 2008 Feb; 335(2):120-5. PubMed ID: 18277120
    [TBL] [Abstract][Full Text] [Related]  

  • 122. Cinacalcet use in pediatric chronic kidney disease. A survey study.
    Al-Ahmad RA; Sheerah AA; Alhasan KA; Kari JA
    Saudi Med J; 2020 May; 41(5):479-484. PubMed ID: 32373914
    [TBL] [Abstract][Full Text] [Related]  

  • 123. Correction of hypercalcaemia by cinacalcet in familial hypocalciuric hypercalcaemia.
    Festen-Spanjer B; Haring CM; Koster JB; Mudde AH
    Clin Endocrinol (Oxf); 2008 Feb; 68(2):324-5. PubMed ID: 17803689
    [No Abstract]   [Full Text] [Related]  

  • 124. Calcimimetics and other simple pharmacological interventions do not work in dialysis: what can we do about it?
    Palmer SC; Strippoli GF
    J Nephrol; 2013; 26(4):599-602. PubMed ID: 23843044
    [TBL] [Abstract][Full Text] [Related]  

  • 125. Cinacalcet treatment in dialysis patients with secondary hyperparathyroidism: effects and open issues.
    Drüeke TB
    Ther Apher Dial; 2008 Oct; 12 Suppl 1():S2-12. PubMed ID: 19032522
    [TBL] [Abstract][Full Text] [Related]  

  • 126. Survey of attitudes of physicians toward the current evaluation and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD).
    Souqiyyeh MZ; Shaheen FA
    Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):93-101. PubMed ID: 20061700
    [TBL] [Abstract][Full Text] [Related]  

  • 127. Use of cinacalcet HCl to achieve the recommended targets of bone metabolism in a patient with therapy-resistant renal hyperparathyroidism.
    Bahner U; Brandl M; Nies C; Schmidt-Gayk H
    J Ren Nutr; 2008 Jul; 18(4):383-8. PubMed ID: 18558304
    [TBL] [Abstract][Full Text] [Related]  

  • 128. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease.
    Torres PU
    J Ren Nutr; 2006 Jul; 16(3):253-8. PubMed ID: 16825031
    [TBL] [Abstract][Full Text] [Related]  

  • 129. Cinacalcet: An oral calcimimetic agent for the management of hyperparathyroidism.
    Dong BJ
    Clin Ther; 2005 Nov; 27(11):1725-51. PubMed ID: 16368445
    [TBL] [Abstract][Full Text] [Related]  

  • 130. [Cinacalcet - an allosteric enhancer at the Ca2+-receptor].
    Kebig A; Mohr K
    Dtsch Med Wochenschr; 2008 Aug; 133(33):1681-3. PubMed ID: 18661462
    [TBL] [Abstract][Full Text] [Related]  

  • 131. Drug Insight: renal indications of calcimimetics.
    Shahapuni I; Monge M; Oprisiu R; Mazouz H; Westeel PF; Morinière P; Massy Z; Choukroun G; Fournier A
    Nat Clin Pract Nephrol; 2006 Jun; 2(6):316-25. PubMed ID: 16932453
    [TBL] [Abstract][Full Text] [Related]  

  • 132. The role of cinacalcet in treating secondary hyperparathyroidism.
    Brommage D; Gallgano C
    Nephrol Nurs J; 2005; 32(2):229-31. PubMed ID: 15889812
    [TBL] [Abstract][Full Text] [Related]  

  • 133.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 134.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 135.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 136.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 137.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 138.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 139.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 140.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.